Shirley S Ong MD

Neurology•Pittsburgh, PA

Neurooncology

Associate professor, Division of Neuro-oncology University of Pittsburgh Medical Center

Join to View Full Profile

5150 Centre AveGround FloorPittsburgh, PA 15232
Phone+1 614-293-4448
Fax+1 614-293-3277

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 2008 - 2010
SSM Health/Saint Louis University School of MedicineResidency, Neurology, 2005 - 2008
SSM Health/Saint Louis University School of MedicineInternship, Internal Medicine, 2004 - 2005
University of the East College of MedicineClass of 1995

Certifications & Licensure

OH State Medical License 2019 - 2026
AR State Medical License 2011 - 2020
IL State Medical License 2010 - 2011
MO State Medical License 2004 - 2008
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation

Clinical Trials

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Available
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects Start of enrollment: 2016 Oct 06
Completed
Phase 2
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma Start of enrollment: 2020 Oct 21
COMPLETED
PHASE2
A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme Start of enrollment: 2021 May 18
Active, not recruiting
Phase 2
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden Start of enrollment: 2020 Dec 24
SUSPENDED
PHASE2
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) Start of enrollment: 2023 Jan 23
RECRUITING
PHASE3
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma Start of enrollment: 2022 Mar 28
RECRUITING
PHASE3
Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases Start of enrollment: 2021 Dec 06
ACTIVE_NOT_RECRUITING
PHASE1
Join now to see all

Publications & Presentations

PubMed

Early Repeat Residual Resection Versus Adjuvant Therapy for Incompletely Resected Glioblastoma: A Case-Control Study.
Mark A Damante, Joshua Vignolles-Jeong, Guilherme Finger, Daniel Kreatsoulas, Santino Cua
Neurosurgery. 2025-02-21
104 citations
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Farshad Nassiri, Vikas Patil, Leeor S Yefet, Olivia Singh, Jeff Liu
Nature Medicine. 2023-06-01
7 citations
Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma.
Jennifer K Matsui, Haley K Perlow, Alex R Ritter, Rituraj Upadhyay, Raju R Raval
Biomedicines. 2022-07-21

Journal Articles

Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R..., Nature Medicine, 6/29/2023

Books/Book Chapters

Neuro-Oncology Compedium for the Boards and Clinical Practice
Chapter: Ependymoma
Iyad Alnahhas, Appaji Rayi, Wayne Slone, Peter Kobalka, Shirley Ong, Pierre Giglio, Vinay K. PuduvalliEditors: Maciej Mrgala, Na Tosha Gaston, Jennifer L. Clarke, Sylvia C. Kurtz, Kathryn S. Nevel.Oxford University PressEdition 1st,2023

Press Mentions

All Slots for Prestigious Neuro-Oncology Fellowship Filled by UAMS ResidentsJune 13th, 2017

Professional Memberships

American Academy of Neurology - AAN
Member
American Society of Clinical Oncology - ASCO
Member
Society for Neuro-oncology
Member